
Yini Wang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1698671/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Serum ferritin is a good indicator for predicting the efficacy of adult HLH induction therapy. Annals of Medicine, 2022, 54, 283-292.	1.5	10
2	Outcomes of allogeneic hematopoietic stem cell transplantation for primary hemophagocytic lymphohistiocytosis in adults. Hematological Oncology, 2022, 40, 390-399.	0.8	1
3	EBV protection†and susceptibilityâ€related HLA alleles and EBV status in the Chinese population: A singleâ€center study. Immunity, Inflammation and Disease, 2022, 10, .	1.3	0
4	A Study on Early Death Prognosis Model in Adult Patients with Secondary Hemophagocytic Lymphohistiocytosis. Journal of Healthcare Engineering, 2022, 2022, 1-7.	1.1	2
5	The DEP regimen is superior to the HLH-1994 regimen as first-line therapy for lymphoma-associated haemophagocytic lymphohistiocytosis. Leukemia and Lymphoma, 2021, 62, 854-860.	0.6	10
6	Characteristics of Epstein–Barr virus reactivation after allogeneic haematopoietic stem cell transplantation in patients with chronic active Epstein–Barr virus disease: favorable responses to rituximab. Bone Marrow Transplantation, 2021, 56, 1449-1451.	1.3	3
7	Epstein-Barr virus infection is an important cause of hemophagocytic lymphohistiocytosis during chemotherapy for lymphoma. Infectious Diseases Now, 2021, 51, 310-311.	0.7	1
8	Successful treatment of cytomegalovirus-induced hemophagocytic lymphohistiocytosis with ruxolitinib as a first-line treatment. Infectious Diseases Now, 2021, 51, 311-313.	0.7	3
9	Epidemiological investigation of hemophagocytic lymphohistiocytosis in China. Orphanet Journal of Rare Diseases, 2021, 16, 342.	1.2	19
10	Ruxolitinib in Patients With Chronic Active Epstein-Barr Virus Infection: A Retrospective, Single-Center Study. Frontiers in Pharmacology, 2021, 12, 710400.	1.6	6
11	Non-EBV infection-associated hemophagocytic lymphohistiocytosis: a distinct subgroup where pathogen-directed therapy is essential and favorable outcomes are expected. Leukemia and Lymphoma, 2021, 62, 1657-1663.	0.6	2
12	Requirement for containing etoposide in the initial treatment of lymphoma associated hemophagocytic lymphohistiocytosis. Cancer Biology and Therapy, 2021, 22, 598-606.	1.5	10
13	Clinical Features and Prognostic Risk Prediction of Non-Hodgkin Lymphoma-Associated Hemophagocytic Syndrome. Frontiers in Oncology, 2021, 11, 788056.	1.3	10
14	Ruxolitinib treatment for SR-aGVHD in patients with EBV-HLH undergoing allo-HSCT. Annals of Hematology, 2020, 99, 343-349.	0.8	15
15	Genotype characteristics and immunological indicator evaluation of 311 hemophagocytic lymphohistiocytosis cases in China. Orphanet Journal of Rare Diseases, 2020, 15, 112.	1.2	14
16	Hodgkin lymphoma-associated hemophagocytic lymphohistiocytosis—a dangerous disease. Annals of Hematology, 2020, 99, 1575-1581.	0.8	5
17	HLA-mismatched GPBSC infusion therapy in refractory Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis: an observational study from a single center. Stem Cell Research and Therapy, 2020, 11, 265.	2.4	0
18	Adult primary hemophagocytic lymphohistocytosis associated with lymphoma. Annals of Hematology, 2020, 99, 663-665.	0.8	1

Yini Wang

#	Article	IF	CITATIONS
19	Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis. Haematologica, 2020, 105, e210-e212.	1.7	91
20	The role of allogeneic hematopoietic stem cell transplantation and Epsteinâ€Barr virus infection on the treatment for child primary hemophagocytic lymphohistiocytosis patients with Xâ€linked lymphoproliferative disease: A rare case report and family survey study. Pediatric Transplantation, 2020, 24, e13635.	0.5	2
21	SOLUBLE ST2 AND CD163 AS POTENTIALBIOMARKERS TO DIFFERENTIATE PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS FROM MACROPHAGE ACTIVATION SYNDROME. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019008.	0.5	15
22	Requirement for etoposide in the initial treatment of Epsteinâ€Barr virus–associated haemophagocytic lymphohistiocytosis. British Journal of Haematology, 2019, 186, 717-723.	1.2	22
23	Recommendations for the management of hemophagocytic lymphohistiocytosis in adults. Blood, 2019, 133, 2465-2477.	0.6	587
24	The inhibitory receptors on NK cells and CTLs are upregulated in adult and adolescent patients with secondary hemophagocytic lymphohistiocytosis. Clinical Immunology, 2019, 202, 18-28.	1.4	13
25	Long-term survival benefit of ruxolitinib in a patient with relapsed refractory chronic active Epstein–Barr virus. Annals of Hematology, 2019, 98, 2003-2004.	0.8	7
26	Successful Outcome of a Case of Acute Myeloid Leukemia With t(8;21)/AML-ETO Following Langerhans Cell Histiocytosis. Turkish Journal of Haematology, 2019, 36, 294-296.	0.2	1
27	Haploidentical hematopoietic stem cell transplantation for adult patients with Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Leukemia and Lymphoma, 2018, 59, 77-84.	0.6	13
28	Multivariate analysis of prognosis for patients with natural killer/T cell lymphoma-associated hemophagocytic lymphohistiocytosis. Hematology, 2018, 23, 228-234.	0.7	27
29	Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis in adults and adolescents—a life-threatening disease: analysis of 133 cases from a single center. Hematology, 2018, 23, 810-816.	0.7	34
30	Primary hemophagocytic lymphohistiocytosis in adults: the utility of family surveys in a single-center study from China. Orphanet Journal of Rare Diseases, 2018, 13, 17.	1.2	22
31	Application of an improved flow cytometry-based NK cell activity assay in adult hemophagocytic lymphohistiocytosis. International Journal of Hematology, 2017, 105, 828-834.	0.7	21
32	Elevation of CD16+CD56+NK-cells and down-regulation of serum interleukin-21 (IL-21) and IL-1α after splenectomy in relapsed hemophagocytic lymphohistiocytosis of unknown cause. Hematology, 2017, 22, 1-7.	0.7	3
33	Treatment of hemophagocytic lymphohistiocytosis. Current Opinion in Hematology, 2017, 24, 54-58.	1.2	27
34	Central nervous system involvement in adults with haemophagocytic lymphohistiocytosis: a single-center study. Annals of Hematology, 2017, 96, 1279-1285.	0.8	37
35	PEG-aspargase and DEP regimen combination therapy for refractory Epstein–Barr virus-associated hemophagocytic lymphohistiocytosis. Journal of Hematology and Oncology, 2016, 9, 84.	6.9	41
36	Allogeneic hematopoietic stem-cell transplantation for adult and adolescent hemophagocytic lymphohistiocytosis: a single center analysis. International Journal of Hematology, 2016, 104, 628-635.	0.7	31

Yini Wang

#	Article	IF	CITATIONS
37	L-DEP Is an Effective Treatment for Adult and Adolescent Patients with Epstein-Barr Virus-Associated Hemophagocytic Lymphohistiocytosis. Blood, 2016, 128, 2521-2521.	0.6	0
38	Multicenter study of combination DEP regimen as a salvage therapy for adult refractory hemophagocytic lymphohistiocytosis. Blood, 2015, 126, 2186-2192.	0.6	137
39	Genetic Features of Late Onset Primary Hemophagocytic Lymphohistiocytosis in Adolescence or Adulthood. PLoS ONE, 2014, 9, e107386.	1.1	65
40	Recombinant human thrombopoietin is an effective treatment for thrombocytopenia in hemophagocytic lymphohistiocytosis. Annals of Hematology, 2013, 92, 1695-1699.	0.8	15
41	Adult onset of primary hemophagocytic syndrome in subjects carrying PRF1 mutations. Annals of Hematology, 2012, 91, 1489-1490.	0.8	7
42	Early diagnostic value of low percentage of glycosylated ferritin in secondary hemophagocytic lymphohistiocytosis. International Journal of Hematology, 2009, 90, 501-505.	0.7	29
43	Study on Treatment of Lymphoma-Associated Hemophagocytic Syndrome with Fludarabine Combined with Methylprednisolone and Globulin. Blood, 2008, 112, 4956-4956.	0.6	0
44	Early Diagnosis and Treatment of the Patients with Acquired Hemophagocytic Lymphohistiocytosis. Blood, 2008, 112, 3552-3552.	0.6	0